Comment from Certara
AnonymousSupportBusiness
Summary: Certara expresses strong support for the draft guidance on QSP-based dose selection for MABEL in FIH trials. They propose specific refinements to improve clarity, model complexity definitions, and alignment with existing FDA frameworks like NAMs and MIDD.
Please find attached the comments on behalf of Certara.
Piet van der Graaf